Exploring the Benefits of Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers
- In LS carriers, immunotheraphy with NOUS-209 off the shelf vaccine is safe and well tolerated
- NOUS-209 elicits robust neoantigen specific T-cell response in 100% of subjects
- Vaccine-induced responses are broad and recognised multiple neoantigens